Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

ArkBio has concluded enrolment and dosing for a Phase I trial of AK0610, to prevent RSV infection, particularly in vulnerable ...

Cybersecurity is another critical issue, as health data is particularly vulnerable to breaches, which can lead to identity ...

The biopharmaceutical industry is being called to take its sustainability efforts to the next level. A new report sheds light ...

The Global Coalition for Adaptive Research (GCAR) has executed an agreement to evaluate AstraZeneca's AZD1390 in the GBM ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous HBV)-specific TCR-T therapy, ...

Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation ...

Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials.

Endeavor has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial of ENV-101 (taladegib) for IPF.